The global endocrine testing market size is calculated at USD 14.39 billion in 2024, grew to USD 15.63 billion in 2025, and is predicted to hit around USD 32.83 billion by 2034, poised to grow at a CAGR of 8.6% between 2024 and 2034. The North America endocrine testing market size accounted for USD 5.90 billion in 2024 and is anticipated to grow at the fastest CAGR of 8.73% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Endocrine Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Endocrine Testing Market, by Test Type, 2024-2034
8.1.1 Estradiol (E2) Test
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Dehydroepiandrosterone Sulfate (DHEAS) Test
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Progesterone Test
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Testosterone Test
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Thyroid Stimulating Hormone (TSH) Test
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Prolactin Test
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Follicle Stimulating Hormone (FSH) Test
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Human Chorionic Gonadotropin (hCG) Hormone Test
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Luteinizing Hormone (LH) Test
8.1.9.1. Market Revenue and Forecast (2021-2034)
8.1.10. Cortisol Test
8.1.10.1. Market Revenue and Forecast (2021-2034)
8.1.11. Insulin Test
8.1.11.1. Market Revenue and Forecast (2021-2034)
8.1.12. Others
8.1.12.1. Market Revenue and Forecast (2021-2034)
9.1. Endocrine Testing Market, by Technology, 2024-2034
9.1.1. Immunoassay
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Chromatography
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Mass Spectroscopy
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Nucleic Acid Based
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. Endocrine Testing Market, by End-User, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Commercial Laboratories
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Ambulatory Care Centers
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-User (2021-2034)
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. bioMerieux SA
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bio-Rad Laboratories Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. DiaSorin S.p.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AB Sciex
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Agilent Technologies Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Ortho Clinical Diagnostics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Laboratory Corporation of America Holdings
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Quest Diagnostics Incorporated
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample